Is Ang Lifesciences India a good stock to invest in?

Ang Lifesciences India can be analyzed on the following key metrics - TTM P/E: - Sector P/E: 22.43 Dividend Yield: 0% D/E ratio: -

Ang Lifesciences India Share Price

Sector: Biotechnology & Drugs

Powered by

28.00 +0.17 (0.61%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 27.90

Today’s High 28.00

52 Week Low 21.03

52 Week High 62.75

Key Metrics

Market Cap (In Cr) 36.56
Beta 1.6
Div. Yield (%) 0
P/B 0.57
TTM P/E -
Sector P/E 22.43
D/E 0.01
Open Price 27.9
Prev Close 27.83

View All Metrics

Ang Lifesciences India Analysis

Price Analysis

1 Week

-1.96%
3 Months

23.24%
6 Month

-36.33%
YTD

-37.25%
1 Year

-45.89%

Risk Meter

48% Low risk
48% Moderate risk
48% Balanced Risk
48% High risk
48% Extreme risk

Ang Lifesciences India News

Companies reporting results on 1 August include Adani Enterprises, Tata Motors, ITC, Sun Pharmaceuticals, Adani Ports & SEZ, Zomato, Dabur India, Kalyan Jewellers India, Aditya Birla Capital, Thermax, Triveni Engineering & Industries, Max Healthcare Institute, and GR Infraprojects, among others. (Photo: Mint)

Premium

Stocks to watch: Ambuja Cements, Maruti, Sun Pharma, M&M, Adani Power, Infosys

9 min read . 01 Aug 2024

ANG Lifesciences is trading below the 5 days, 20-day, 50-day, 100-day, and 200-day moving averages according to the last traded price.

Premium

Multibagger pharma stock announces record date for bonus issue

1 min read . 03 Jul 2022

Multibagger stock has been under profit-taking heat after climbing to its life-time high of ₹800.45 levels on BSE in November 2021. (HT)

Premium

Multibagger stock to consider 1:4 bonus share issue. Details here

1 min read . 07 Jun 2022

Multibagger stock: If an investor had invested ₹1 lakh in this counter one month ago, its ₹1 lakh would have become ₹1.22 lakh in this period. (HT)

Premium

This multibagger pharma stock gives 650% return in 6 months. Do you own?

2 min read . 17 Sep 2021

View More News

Ang Lifesciences India Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2025

Total Revenue
92.85

Selling/ General/ Admin Expenses Total
17.45

Depreciation/ Amortization
6.76

Other Operating Expenses Total
18.04

Total Operating Expense
101.87

Operating Income
-9.03

Net Income Before Taxes
-15.7

Net Income
-12.41

Diluted Normalized EPS
-9.42

Period
2024

Total Revenue
146.11

Selling/ General/ Admin Expenses Total
19.35

Depreciation/ Amortization
8.37

Other Operating Expenses Total
21.99

Total Operating Expense
146.56

Operating Income
-0.45

Net Income Before Taxes
-10.71

Net Income
-10.14

Diluted Normalized EPS
-6.99

Period
2023

Total Revenue
219.89

Selling/ General/ Admin Expenses Total
32.7

Depreciation/ Amortization
9.35

Other Operating Expenses Total
14.74

Total Operating Expense
206.43

Operating Income
13.46

Net Income Before Taxes
2.63

Net Income
-0.26

Diluted Normalized EPS
-4.73

Period
2022

Total Revenue
354.3

Selling/ General/ Admin Expenses Total
21.29

Depreciation/ Amortization
5.88

Other Operating Expenses Total
37.54

Total Operating Expense
292.69

Operating Income
61.61

Net Income Before Taxes
53.5

Net Income
40.32

Diluted Normalized EPS
31.17

Period
2021

Total Revenue
154.38

Selling/ General/ Admin Expenses Total
13.68

Depreciation/ Amortization
1.32

Other Operating Expenses Total
22.88

Total Operating Expense
141.83

Operating Income
12.55

Net Income Before Taxes
10.14

Net Income
7.03

Diluted Normalized EPS
5.42

Period
2020

Total Revenue
126.83

Selling/ General/ Admin Expenses Total
7.94

Depreciation/ Amortization
1.23

Other Operating Expenses Total
17.84

Total Operating Expense
115.98

Operating Income
10.85

Net Income Before Taxes
8.41

Net Income
6.1

Diluted Normalized EPS
4.7

Period
2019

Total Revenue
121.7

Selling/ General/ Admin Expenses Total
6.39

Depreciation/ Amortization
1.12

Other Operating Expenses Total
16.06

Total Operating Expense
111.48

Operating Income
10.22

Net Income Before Taxes
8.11

Net Income
5.65

Diluted Normalized EPS
4.4

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Ang Lifesciences India Technical

Moving Average SMA

5 Day28.34
10 Day29.06
20 Day29.26

50 Day28.41
100 Day30.65
300 Day39.11

Ang Lifesciences India Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Gujarat Inject Kerala
24.55
-0.61
-2.42
29.12
13.11
35.81

Veerhealth Care
18.54
0.26
1.42
27
9.29
36.94

Ang Lifesciences India
28
0.17
0.61
62.75
21.03
36.56

Transgene Biotek
4.42
-0.09
-2
10.84
3.22
29.07

Panjon
18.91
-0.23
-1.2
40.18
17.61
32.1

Ang Lifesciences India Shareholding

Shareholding Pattern

*Promoter pledging: 31.68%

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

30-May-25
Audited Results

14-Feb-25
Quarterly Results

14-Nov-24
Quarterly Results

14-Aug-24
Quarterly Results

30-May-24
Audited Results

14-Feb-24
Quarterly Results

14-Nov-23
Quarterly Results

14-Aug-23
Quarterly Results

30-May-23
Audited Results

06-Mar-23
Preferential issue of shares

Meeting Date
Announced on
Purpose

30-Sept-24
18-Sept-24
AGM

30-Sept-23
05-Sept-23
AGM

03-May-23
10-Apr-23
EGM

01-Apr-23
10-Mar-23
EGM

30-Sept-22
05-Sept-22
AGM

10-Sept-21
10-Aug-21
POM

Announced on
Record Date
Ex-Dividend
Dividend Value

25-Oct-21
04-Nov-21
02-Nov-21
1

Announced on
Record Date
Ex-Bonus
Description

30-May-22
14-Jul-22
13-Jul-22
Bonus issue in the ratio of 1:4 of Rs. 10/-

06-Aug-21
23-Sept-21
22-Sept-21
Bonus issue in the ratio of 1:1 of Rs. 10/-

View All

Company Profile

ABOUT Ang Lifesciences India

Industry Biotechnology & Drugs
ISIN INE236W01016
BSE Code 540694

ANG Lifesciences India Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials. It operates in two segments, namely pharmaceuticals and printing and packaging. The Company's product portfolio includes various products comprising therapeutic categories, such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin and Beta Lactamase Inhibitor. The Company’s product category includes Dry Powder Injection, Liquid Injections, Hard Gelatin Capsule, Tablet Beta Lactum, Tablets, Liquid Suspension /Syrup, Ointment/Creams, and Soft Gelatin Capsule. Its Dry Powder Injection products include Ampicillin & Cloxacillin for injection 500mg, Azetronam for Injection USP 500mg, Ampicillin Injection 1.0gm, Ceftriaxone Injection 250mg, Amoxycillin & Potassium Clavulanate for injection 1.2gm, and others.

MANAGEMENT

Harshita Aggarwal Compliance Officer, Company Secretary
Rajesh Gupta Managing Director, Director

ANG LIFESCIENCES INDIA SUMMARY

Ang Lifesciences India is trading 0.61% upper at Rs 28.00 as compared to its last closing price. Ang Lifesciences India has been trading in the price range of 28.00 & 27.90. Ang Lifesciences India has given -37.25% in this year & -1.96% in the last 5 days.

The company posted a net profit of -2.06 Crores in its last quarter.

Listed peers of Ang Lifesciences India include Gujarat Inject Kerala (-2.42%), Veerhealth Care (1.42%), Ang Lifesciences India (0.61%) etc.

Ang Lifesciences India has a 70.6% promoter holding & 29.4% public holding.

FAQs about Ang Lifesciences India

Ang Lifesciences India is trading at 28.00 as on 27 Jun, 2025 3:15:00 PM. This is 0.61% upper as compared to its previous closing price of 27.83

The market capitalization of Ang Lifesciences India is 36.56 Cr as on 27 Jun, 2025 3:15:00 PM.

The 52 wk high for Ang Lifesciences India is 62.75 whereas the 52 wk low is 21.03

Ang Lifesciences India can be analyzed on the following key metrics -

TTM P/E: -
Sector P/E: 22.43
Dividend Yield: 0%
D/E ratio: -

Ang Lifesciences India reported a net profit of -12.41 Cr in 2025.

Ang Lifesciences India Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Ang Lifesciences India Share Price

Price Range

Key Metrics

Ang Lifesciences India Analysis

Ang Lifesciences India News

Stocks to watch: Ambuja Cements, Maruti, Sun Pharma, M&M, Adani Power, Infosys

Multibagger pharma stock announces record date for bonus issue

Multibagger stock to consider 1:4 bonus share issue. Details here

This multibagger pharma stock gives 650% return in 6 months. Do you own?

Ang Lifesciences India Financials

Forecast

Forecast

Forecast

Ang Lifesciences India Technical

Ang Lifesciences India Peers

Ang Lifesciences India Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Ang Lifesciences India

MANAGEMENT

ANG LIFESCIENCES INDIA SUMMARY

FAQs about Ang Lifesciences India

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue